IMS has earned a spot on IDC Health Insights’ list of top 5 preferred life science technology vendors for IT services. The ranking is based on the global market intelligence firm’s survey of 135 industry leaders on their planned IT spend.
Fewer than 1% of pharma product launches outperform the market. But following best practices can help improve the odds. IMS has compiled best practices into a pragmatic framework for launch success, based on research from over 4,000 launches across eight major markets.
Generic injectable and oncology drugs make up the largest share of shortages, says an IMS Institute for Healthcare Informatics study. An early warning system could minimize future disruptions.